Surveillance of antibiotic susceptibility of urinary tract pathogens for a population of 5.6 million over 4 years

The Journal of Antimicrobial Chemotherapy
Dean IronmongerPeter M Hawkey

Abstract

To retrospectively analyse routine susceptibility testing data to describe antimicrobial non-susceptibility trends in isolates of Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa from urine samples in a population of 5.6 million people over a 4 year period. De-duplicated laboratory data submitted to the AmSurv surveillance system from the West Midlands region of England and results of submissions to the Antimicrobial Resistance and Healthcare Associated Infections Reference Unit were extracted for the period 2010-13. Descriptive analysis of the non-susceptibility of selected Gram-negative organisms to key antibiotics, as recommended for monitoring in the UK Five Year Antimicrobial Resistance Strategy, was undertaken. During the study period, there were 431 461 reports for E. coli, 23 786 for K. pneumoniae and 6985 for P. aeruginosa from urine specimens. These represented 61%, 3% and 1%, respectively, of all organisms isolated from urine specimens. There was a linear increase in non-susceptibility to third-generation cephalosporins for E. coli and K. pneumoniae, and to ciprofloxacin for E. coli, in specimens from both hospital and community settings (P < 0.001). The proportions of E. coli and K. pneumoniae repo...Continue Reading

References

Jun 5, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·K GuptaW E Stamm
Sep 14, 2007·The Journal of Antimicrobial Chemotherapy·Andrew C HaywardUNKNOWN Surveillance Subgroup of SACAR
Jun 20, 2008·Annals of Clinical Microbiology and Antimicrobials·David C BeanDavid W Wareham
Mar 2, 2011·Antimicrobial Agents and Chemotherapy·Gabriel CabotUNKNOWN Spanish Network for Research in Infectious Diseases (REIPI)
May 4, 2011·Antimicrobial Agents and Chemotherapy·James A KarlowskyGeorge G Zhanel
Mar 6, 2012·International Journal of Antimicrobial Agents·David M Livermore
May 21, 2013·The Journal of Antimicrobial Chemotherapy·Dean IronmongerPeter M Hawkey
Jun 20, 2014·The Journal of Antimicrobial Chemotherapy·Jérôme RobertUNKNOWN ONERBA's Carbapenem Resistance Study Group

❮ Previous
Next ❯

Citations

Mar 31, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·James R JohnsonEvgeni Sokurenko
Jun 30, 2016·The Journal of Antimicrobial Chemotherapy·Teh Li ChinAlasdair MacGowan
Sep 21, 2016·International Journal of Environmental Research and Public Health·Wellington Francisco RodriguesCarlo José Oliveira
Nov 22, 2017·The British Journal of General Practice : the Journal of the Royal College of General Practitioners·Christopher C ButlerTheo Verheij
Jan 13, 2017·The Journal of Antimicrobial Chemotherapy·Alicia RoselloSarah R Deeny
May 20, 2020·Infection and Drug Resistance·Jide SunXiuyu Xu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.